Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | DDO | Q99489 | 2/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425721 | 0.84 | HSD17B1 (0.55) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL8531852 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL598230 | 0.83 | CYP1A2 (0.65) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL2964707 | 0.81 | CYP1A2 (0.48) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29853939 | 0.80 | CYP1A2 (0.75) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10560099 | 0.80 | CYP1A2 (0.62) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL11629826 | 0.80 | CYP1A2 (0.75) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL24895086 | 0.79 | GRIN2D (0.62) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL14381082 | 0.79 | GRIN2D (0.72) | CYP1A2ALDH1A1HPGDHSD17B10GRIN2D | |
| SCHEMBL29845609 | 0.78 | CYP1A2 (0.60) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170336728-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | CANON KABUSHIKI KAISHA (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170217999-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| US-6878659-B2 | Solid catalyst component for olefin polymerization and catalyst | TOHO TITANIUM CO., LTD. (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20040072681-A1 | Solid catalyst component for olefin polymerization and catalyst | TOHO TITANIUM CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1260524-A1 | SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST | Toho Titanium Co., Ltd. (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217999-A1 | SURFACE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, GRIN1 | CYP1A2 2409/4885CYP2A6 2166/4885ALDH1A1 1177/4885 |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | CYP1A2 3099/4885CYP2A6 955/4885ALDH1A1 3499/4885 |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | CYP1A2 299/4885CYP2A6 12/4885ALDH1A1 1597/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | CYP1A2 1090/4885CYP2A6 182/4885ALDH1A1 1189/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | CYP1A2 3099/4885CYP2A6 955/4885ALDH1A1 3499/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | CYP1A2 4406/4885CYP2A6 1474/4885ALDH1A1 3257/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | CYP1A2 3453/4885CYP2A6 1150/4885ALDH1A1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.